Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;11(2):237-47.
doi: 10.2217/pgs.09.176.

Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities

Craig P Hersh  1
Affiliations
Review

Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities

Craig P Hersh. Pharmacogenomics. 2010 Feb.

Abstract

Similar to other common chronic diseases, chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder with multiple disease subtypes. Candidate gene studies have found genetic associations for COPD-related phenotypes that may be relevant for pharmacogenetics studies, including lung function decline and COPD exacerbations. However, few COPD pharmacogenetics studies have been completed. Most studies have focused on the role of variants in the beta(2)-adrenergic receptor gene on bronchodilator response, but the findings have been inconclusive. Candidate gene studies highlight the concept that genes for COPD susceptibility may also be relevant in COPD pharmacogenetics. Currently, there are no clinical applications of pharmacogenetics to COPD therapy, but the use of pharmacogenetics to determine initial smoking cessation therapy may be closer to clinical application.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Chronic obstructive pulmonary disease heterogeneity is relevant to pharmacogenetics
Treatment X is effective in chronic obstructive pulmonary disease patients with airway disease but not emphysema. SNPs 3 and 4, both of which are associated with airway disease, will appear to be determinants of treatment response if chronic obstructive pulmonary disease subtypes are not considered or are unknown.
See this image and copyright information in PMC

References

    1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256–1276. - PubMed

    2. ▪▪ Initial report of the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), providing a comprehensive review of chronic obstructive pulmonary disease (COPD) evaluation and treatment.

    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill Summ. 2002;51(6):1–16. - PubMed
    1. Morbidity and Mortality: 2007 Chart Book on Cardiovascular, Lung, and Blood Diseases. NIH: National Heart, Lung, and Blood Institute; MD, USA: 2007.
    1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. - PubMed

    2. ▪▪ More recent update of the original GOLD report.

    1. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497–1505. - PubMed

Publication types

MeSH terms

Substances